drugset / Trial / NCT00113802
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether epratuzumab provides effective therapy in Waldenström's Macroglobulinemia (WM).
Timeline
- Start
- 2004-08
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epratuzumab | Monoclonal antibody | 360 mg/m2 | Intravenous |